Clinical Practice Guidelines for the Management of Congenital Syphilis in Japan, 2023: Executive Summary

Yoshinori Ito, Takuya Yamagishi, Chiaki Ikenoue, Naruhiko Ishiwada, Kenta Ito, Sota Iwatani, Kazunobu Ouchi, Kei Kawana, Hiroyuki Shimizu, Masayoshi Shinjoh, Noriko Takeuchi, Takeshi Tsugawa, Takanori Funaki, Munehiro Furuichi, Tadashi Hoshino, Hiroshige Mikamo, Isao Miyairi, Hiroyuki Moriuchi, Ichiro Morioka, Yuka YamagishiMasaaki Mori

Research output: Contribution to journalReview articlepeer-review

Abstract

Congenital syphilis (CS) is a mother-to-child infection caused by the bacterium Treponema pallidum, transmitted through the placenta. In Japan, the number of syphilis cases has recently increased, accompanied by an increase in CS cases. Thus, automated methods for serum antibodies with serial values, without a 2× dilution sequence, have been widely used. Moreover, benzathine penicillin G was introduced in Japan in 2021. In response to the recent surge in CS, the first edition of the clinical practice guidelines for the management of CS was developed by a committee comprising representatives from 4 Japanese medical societies. This summary outlines 5 clinical questions with statements and expert comments regarding diagnosis, treatment and follow-up requirements. These guidelines aim to assist in the management of patients with CS infection.

Original languageEnglish
Pages (from-to)e90-e94
JournalPediatric Infectious Disease Journal
Volume44
Issue number3
DOIs
Publication statusPublished - 2025 Mar 1
Externally publishedYes

Keywords

  • Japan
  • congenital syphilis
  • guideline
  • syphilis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical Practice Guidelines for the Management of Congenital Syphilis in Japan, 2023: Executive Summary'. Together they form a unique fingerprint.

Cite this